Project Grant 2451554
Award Date
3/1/25
Completion Date
2/28/26
Dollars Obligated
$305K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Durham, NC 27701, USA
Similar Awards
This Project Grant award of $305,000.00 from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a rapid point-of-care antimicrobial susceptibility testing (AST) kit. The goal is to create a microfluidic-based platform that can provide actionable AST results within 6-9 hours, compared to the current 3-5 day turnaround, to help physicians prescribe the optimal antibiotic dosage sooner. This will reduce...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,362 to RT Microdx Inc. focuses on developing a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-quality accuracy for use by non-healthcare professionals in non-clinical settings, enabling rapid and reliable pathogen detection at home. Key technical objectives include optimizing the platform's...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project will establish the feasibility of leveraging mutational signatures in bacterial DNA to identify antibiotic resistance status, including the potential for rapid development of multi-drug resistance. This approach...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project grant, awarded to Anvil Diagnostics Inc. in the amount of $298,646, aims to develop a rapid diagnostic test for sepsis-causing pathogens in plasma samples using digital PCR hardware. The proposed technology seeks to comprehensively identify and quantify a panel of 17 common sepsis-causing pathogens within 4 hours from small blood volumes,...
This Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) is supporting the development of a miniaturized, sensitive, and user-friendly electromagnetic sensing platform to enable rapid diagnostics for bacterial infections. The $448,818 award, spanning from April 1, 2025 to March 31, 2030, aims to create a system that combines physics-based dielectric spectroscopy and biochemistry-based magnetic nanoparticle detection to distinguish bacterial...
This $991,832 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel rapid antibiotic susceptibility testing (AST) platform by Astek Diagnostics Inc., a minority-owned small business in Halethorpe, Maryland. The project aims to adapt the company's previously developed urine cartridge technology for use with cerebrospinal fluid and wound effluent specimens, characterize...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $984,381 to Cobio Diagnostics Inc. in Aurora, Colorado aims to expand a diagnostic tool that enables rapid, direct-from-specimen identification and antimicrobial susceptibility testing of major bloodborne bacterial pathogens. The project will develop a regulatory pathway for FDA clearance, characterize antibodies to expand the test, and validate the expanded tests...
Nanopath Inc. received a $255,874 Project Grant award from the National Science Foundation Division of Industrial Innovation on January 1, 2022 for its "Integrated Point-of-Care System for Rapid Pathogen Identification in Urinary Tract Infections" project. The award is part of the NSF's Engineering program (CFDA 47.041), which seeks to improve quality of life and economic strength through engineering research and education. Under the award, Nanopath will develop an integrated...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...